Pay in 4 interest-free payments of $5.50 Learn more
Ships within 48 hours · Estimated delivery Oct 22 - Oct 27
Applying REWIND cardiovascular disease criteria to SUSTAIN 6 and LEADER (comparative analysis of GLP-1 cardiovascular outcome trials)
Moreover, GLP-1RAs have neuroprotective, anti-infectious, cardiovascular protective, and metabolic regulatory effects, exhibiting good application prospects
International heart journal
Bolyen E, Rideout JR, Dillon MR, Bokulich NA, Abnet CC, Al-Ghalith AG, et al
This is actually an advantage
US$ 24.33
US$ 28.54
US$ 20.56
US$ 27.32
US$ 25.07
US$ 27.17
